Abstract
Understanding the geographical distribution of COVID-19 through the general population is key to the provision of adequate healthcare services. Using self-reported data from 2,266,235 unique GB users of the COVID Symptom Tracker app, we find that COVID-19 prevalence and severity became rapidly distributed across the UK within a month of the WHO declaration of the pandemic, with significant evidence of urban hot-spots. We found a geo-social gradient associated with disease severity and prevalence suggesting resources should focus on urban areas and areas of higher deprivation. Our results demonstrate use of self-reported data to inform public health policy and resource allocation.
Competing Interest Statement
DS is a consultant to Zoe Global Ltd (Zoe). SG, JC, EB, RD, JW are or have been employees of Zoe Global Limited. Other authors have no conflict of interest to declare.
Clinical Trial
NA
Funding Statement
This work was supported by Zoe Global. The Department of Twin Research is funded by the Wellcome Trust, Medical Research Council, European Union, Chronic Disease Research Foundation (CDRF), Zoe Global Ltd and the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust in partnership with Kings College London. CM is funded by the Chronic Disease Research Foundation and by the MRC Aim-Hy project grant. CHS is an Alzheimers Society Junior Fellowship AS-JF-17-011; SO and MJC are funded by the Wellcome/EPSRC Centre for Medical Engineering (WT203148/Z/16/Z), Wellcome Flagship Programme (WT213038/Z/18/Z). We express our sincere thanks to all the participants of the COVID Symptom Tracker app. We thank the staff of Zoe Global Limited, the Department of Twin Research for their tireless work in contributing to the running of the study and data collection.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymised research data will be shared with third parties via the centre for Health Data Research UK (HDRUK.ac.uk). Data updates can be found on https://covid.joinzoe.com
